Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ALCOCID is a finished generic pharmaceutical combination formulation developed and marketed by Zytras Life Sciences. It is composed of sucralfate (1000mg) and oxetacaine (20mg) in a syrup/suspension form. Sucralfate acts as a mucosal protective agent; in the acidic environment of the stomach, it polymerizes to form a viscous, adhesive paste that binds to the surface of ulcers, creating a physical barrier against gastric acid, pepsin, and bile salts. Oxetacaine is a potent local anesthetic that remains effective at low pH levels; it provides rapid pain relief by numbing the gastric mucosa and may also inhibit the release of gastrin, thereby reducing acid production. The medication is primarily used to treat acidity, heartburn, gastroesophageal reflux disease (GERD), and both gastric and duodenal ulcers.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ALCOCID.